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Legends	for	Figures		
	
Figure	1.	Structure	of	duocarmycin	SA	1;	seco-CBI-TMI	2;	seco-iso-CFI-TMI	or	tafuramycin	A	or	
TfA	3;	3a	is	the	putative	active	cyclopropane	drug	of	tafuramycin	A,	and	its	reaction	with	
adenine-N3;	and	seco-iso-CFI-Hx	or	HxTfA	4.	
	
Figure	2.	Synthesis	of	HxTfA	4.	
	
Figure	3.	Autoradiogram	of	a	thermal	cleavage	gel	showing	purine–N3	lesions	on	the	bottom	
strand	of	a	5’-32P-labeled	208-bp	fragmemt	of	pUC18.	G+A	lane;	0,	control;	TfA	3:	0.1,	0.3,	1,	3,	
10,	and	30	µM;	and	HxTfA	4:	0.1,	0.3,	1,	3,	10,	and	30	µM.	
	
Figure	4.	(A)	Visualization	of	HxTfA	4	nuclear	uptake.	A549	cells	were	treated	with	the	indicated	
concentrations	of	HxTfA	(0,	control;	0.5,	1.0,	and	5.0	µM)	for	24	h,	washed	with	PBS,	and	fixed	
with	2%	paraformaldehyde	(PFA).	They	were	subsequently	permeabilized	and	the	nuclei	were	
stained	with	propidium	iodide	(PI)	before	confocal	microscopy	imaging.	The	composite	image	
presents	the	superimposed	overlay	of	HxTfA	fluorescence	and	the	PI	fluorescence.	No	HxTfA	
fluorescent	signal	was	detected	in	the	control,	untreated	cells	under	the	same	observation	
settings.	(B)	Fluorescence	microscopy	of	A549	cells	treated	overnight	with	50	and	100	µM	
HxTfA,	with	the	corresponding	controls.	Non-fixed,	non-permeabilised	cells	were	
counterstained	with	the	fluorescent	MitoTracker	dye	(150	nM),	which	selectively	stains	active	
mitochondria	in	live	cells,	and	were	immediately	observed	by	microscopy.	The	composite	image	
presents	the	superimposed	HxTfA	fluorescence	and	the	Mitotracker	fluorescence.	
	
Figure	5.	Effects	of	TfA	3	and	HxTfA	4,	on	cellular	apoptosis-related	proteins	and	on	DNA	
damage	response.	A549	cells	were	pre-treated	with	the	indicated	concentrations	of	TfA	3	and	
HxTfA	4	for	5	h.	After	24	h	in	drug	free	medium,	the	cells	were	analysed	by	immunoblotting	and	
confocal	microscopy.	(A)	Results	from	immunoblotting	experiments,	detecting	the	levels	of	
survivin	and	bcl-xL	in	treated	and	control	A549	cells.	(B)	Immunodetection	of	the	levels	of	
cleaved	caspase-3	and	γ-H2AX	in	treated	and	control	cells.	(C)	Confocal	microscopy	images	of	γ-
H2AX	foci	in	treated	and	control	cells.	
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Cell	Lines	and	Culture	Conditions	
	
A549	cells	were	obtained	from	the	European	Collection	of	Cell	Cultures	and	maintained	in	
Dulbecco’s	Modified	Eagles	Medium	(DMEM)	containing	2	mM-L	glutamine	and	10%	FCS.	The	
cell	lines	was	maintained	in	a	humidified	atmosphere	at	37	°C	with	5%	Carbon	dioxide	(CO2).		
	
Thermal	Cleavage	assay	was	conducted	on	the	same	DNA	fragment	and	under	identical	
experimental	conditions	as	in	8b.	
	
HxTfA	visualization	studies.	Confocal	microscopy	for	the	visualization	of	HxTfA,	were	conducted	
as	in	17a,c	using	the	Zeiss	510	UV-vis	microscope	and	the	LSM510	software.	Briefly,	A549	cells	
were	grown	on	13-mm	glass	cover	slips	and	were	treated	with	different	concentrations	of	4	for	
24	h.	Cells	were	fixed	(2%	PFA),	washed	with	PBS	and	then	permeabilised	to	allow	nuclear	DNA	
staining	with	PI	(2	µg/ml).		
Fluorescence	microscopy	studies	were	conducted	with	a	Leica	DM	R	HC	microscope	(63x	
immersion	oil	lense),	images	captured	by	SPOT	Insight	2Mp	Monochrome	FireWire	Digital	
Camera	and	the	VisiView®	software.	Cells	were	counterstained	with	the	Mitrotracker®Red	
CMXRos	(Thermofisher	scientific)	without	fixation	or	permeabilisation.		
	
Immunoblotting	was	conducted	as	in	17a,c.	The	Bcl-xL,	Survivin,	and	Cleaved	Caspase-3	
antibodies	(Cell	Signalling	Technology)	were	used	at	a	1:1000	dilution,	while	the	β-Actin	(Cell	
Signalling	Technology)	at	a	1:2000	dilution.	For	the	detection	of	phosphorylated	histone	H2A.X	
(Ser139),	the	respective	monoclonal	antibody	(Millipore)	was	used	at	a	1:1000	dilution.		
	
Immunofluorescence	staining	for	γ-H2A.X	was	performed	as	in	17a,c.	Briefly,	A549	cells	were	
washed	with	PBS,	fixed	with	2%	PFA	and	permeabilised	with	PBS	containing	0.5%	Triton	X-100.	
Cells	were	subsequently	blocked	in	PBS	5%	BSA	for	1	h	and	incubated	with	anti-phospho-
Histone	H2A.X	mouse	monoclonal	antibody	(1:100;	Millipore)	diluted	in	PBS	1%	BSA	for	1h.	
After	three	washes,	cells	were	incubated	with	the	goat	anti-mouse	secondary	antibody	Alexa	
Fluor	488	(1:100;	Life	Technologies)	for	another	hour.	Following	a	further	three	washes	in	PBS	
0.1%	Triton	X-100,	nuclei	were	stained	using	a	PI	solution	(2	µg/ml;	Sigma-Aldrich).	γ-H2AX	
levels	were	finally	visualised	using	confocal	microscopy.	
	
	
	
	
	
	
	
	
	
	
	
	
		
